Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEQEMBI vs ADUHELM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lecanemab is a humanized monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.
Treatment of Alzheimer disease (early stage)
Treatment of Alzheimer's disease (FDA approved for patients with mild cognitive impairment or mild dementia stage of disease)
10 mg/kg intravenously every 2 weeks, administered over approximately 1 hour.
10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.
Terminal half-life approximately 7.6 days (range 5-12 days) after multiple doses; supports monthly dosing.
Terminal elimination half-life is approximately 26 days (range 19–34 days), supporting monthly intravenous dosing. The long half-life reflects the slow clearance of Ig G1 monoclonal antibodies.
Metabolized by catabolism via general protein degradation pathways; no CYP450 involvement.
Aducanumab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous Ig G. No specific cytochrome P450 enzymes are involved.
Primarily catabolized to amino acids; not excreted renally or hepatically in unchanged form.
ADUHELM is eliminated primarily via catabolism into small peptides and amino acids. No renal or biliary excretion of intact monoclonal antibody is expected. Clearance is via the reticuloendothelial system; approximately 97% is metabolized, with <3% excreted as intact antibody in urine.
Not determined; lecanemab is a monoclonal antibody with minimal nonspecific binding.
Approximately 99% bound, primarily to endogenous Ig G (via Fc Rn binding) and other plasma proteins; specific binding proteins include Fc Rn.
Approximately 0.122 L/kg (central volume), consistent with limited extravascular distribution typical of m Abs.
Volume of distribution is approximately 6.8 L (central compartment), equivalent to plasma volume; does not distribute extensively into tissues due to large molecular size. In L/kg: ~0.1 L/kg for a 70 kg patient.
IV administration only; bioavailability 100% for intended route.
Intravenous administration results in 100% bioavailability. No subcutaneous or oral formulation is available; thus no bioavailability for other routes.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy in pediatric patients have not been established. No dosing recommendations available.
Safety and efficacy have not been established in pediatric patients. No recommended dosing available.
No specific dose adjustment required based on age alone. Dosing is based on body weight (10 mg/kg) every 2 weeks. Clinical studies included patients up to 90 years of age.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed.
Lecanemab may cause amyloid-related imaging abnormalities (ARIA), including ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). ARIA can be serious and life-threatening.
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Aducanumab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be serious and life-threatening. ARIA generally occurs within the first 8 doses. Monitoring with MRI is required prior to and during treatment.
Risk of ARIA (amyloid-related imaging abnormalities), including ARIA-E and ARIA-H,Risk of infusion-related reactions,Risk of hypersensitivity reactions
Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H,Hypersensitivity reactions including angioedema and urticaria,Risk of seizures (reported in clinical trials),Concomitant use of antithrombotic medications may increase risk of intracranial hemorrhage
History of serious hypersensitivity to lecanemab or any excipients
Known hypersensitivity to aducanumab or any excipients of ADUHELM
No known food interactions. Grapefruit or other CYP450 substrates have no significant interaction. Avoid alcohol due to potential additive CNS effects, though no direct interaction established.
No specific food interactions reported. Patients should maintain a balanced diet as part of overall health management. Avoid grapefruit juice if taking other medications metabolized by CYP3A4, though aducanumab is not metabolized by CYP enzymes.
LEQEMBI (lecanemab) is an anti-amyloid beta monoclonal antibody. There are no adequate human studies on fetal risk. In animal reproductive studies, no adverse developmental effects were observed at doses up to 15 times the human exposure. However, Ig G antibodies are known to cross the placenta, with increasing transfer during the third trimester. Therefore, potential fetal exposure occurs, especially in later pregnancy. Risk cannot be excluded; use only if maternal benefit outweighs fetal risk.
No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal reproductive studies available. Use only if benefit outweighs potential risk.
It is unknown whether lecanemab is excreted in human milk or absorbed systemically after ingestion. Given the large molecular size (monoclonal antibody), excretion into milk is likely low, but not studied. M/P ratio is not available. Caution is advised; consider developmental benefits of breastfeeding versus potential exposure.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Aducanumab is a large Ig G molecule; likely excreted into milk in low amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with mother's clinical need.
No pharmacokinetic data in pregnancy. Monoclonal antibodies typically have altered clearance in pregnancy, but no specific dose adjustment recommendations are established. Use the standard dose (10 mg/kg IV every 2 weeks) unless individual factors dictate otherwise. Consider potential for increased volume of distribution and altered renal clearance; however, no formal guidance exists.
No pharmacokinetic data during pregnancy. Dose adjustments not established. Administer same dose as non-pregnant adults (10 mg/kg IV monthly after titration) unless significant infusion reactions occur.
LEQEMBI (lecanemab) is an anti-amyloid beta monoclonal antibody for early Alzheimer disease. Confirm patient eligibility via amyloid PET or CSF analysis. Administer via IV infusion over approximately 1 hour every 2 weeks. Monitor for amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema) and ARIA-H (hemorrhage), with MRI scans before the 5th, 7th, and 14th infusions. Assess for headache, confusion, or visual changes as potential ARIA symptoms. Patients with homozygous APOE4 genotype have higher risk of ARIA; consider APOE genotyping. Concomitant use of antithrombotic agents may increase risk of ARIA-H; weigh risks versus benefits. Do not abruptly discontinue; no tapering required. Lecanemab is not approved for mild, moderate, or severe Alzheimer disease beyond early stage.
ADUHELM (aducanumab-avwa) is a monoclonal antibody targeting aggregated forms of beta-amyloid. It is indicated for Alzheimer disease. Confirmation of amyloid beta pathology via PET or CSF is required before initiation. Titration over 6-8 months is mandatory to reduce risk of amyloid-related imaging abnormalities (ARIA). Monitor for ARIA with MRI prior to the 7th and 12th infusions; suspend dosing if ARIA is detected. Adverse effects include ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition). Coadministration with anticoagulants may increase risk of ARIA-H. Assess for hypersensitivity reactions. No specific reversal agent is available.
LEQEMBI is used to treat early Alzheimer disease and works by reducing amyloid plaques in the brain.,This medication is given as an intravenous (IV) infusion every 2 weeks, each lasting about 1 hour.,You will need regular MRI scans to check for brain swelling or small bleeds (ARIA).,Tell your doctor immediately if you have new headache, confusion, vision changes, dizziness, or trouble walking.,Inform your healthcare provider about all other medicines, especially blood thinners like warfarin, apixaban, or aspirin.,Do not abruptly stop treatment; consult your doctor if you need to discontinue.
This drug is for patients with mild cognitive impairment or mild Alzheimer disease confirmed by amyloid PET or CSF testing.,Treatment requires intravenous infusion every 4 weeks, with dose titration over at least 6 months.,MRI scans are needed before and during treatment to monitor for brain swelling or small bleeds (ARIA).,Tell your doctor immediately if you experience headache, confusion, dizziness, vision changes, nausea, or seizures.,Avoid blood thinners like warfarin, apixaban, or rivaroxaban unless prescribed; they may increase bleeding risk.,Do not drive or operate heavy machinery if you experience dizziness or visual disturbances.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Store vials in refrigerator and protect from light; do not freeze or shake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEQEMBI vs ADUHELM, answered by our medical review team.
LEQEMBI is a Monoclonal Antibody that works by Lecanemab is a humanized monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.. ADUHELM is a Anti-Amyloid Beta Monoclonal Antibody that works by Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEQEMBI and ADUHELM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEQEMBI is: 10 mg/kg intravenously every 2 weeks, administered over approximately 1 hour.. The standard adult dose of ADUHELM is: 10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEQEMBI and ADUHELM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEQEMBI is classified as Category C. LEQEMBI (lecanemab) is an anti-amyloid beta monoclonal antibody. There are no adequate human studies on fetal risk. In animal reproductive studies, no adverse developmental effects. ADUHELM is classified as Category C. No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal repr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.